Treatment of membranoproliferative glomerulonephritis associated with hepatitis C virus infection

Internal Medicine

Volumn 39, Issue 10, 2000, Pages 788-793

  Nishi, Shinichi ^a   Ueno, Mituhiro ^a   Shimada, Hisaki ^a   Oosawa, Yutaka ^a   Iino, Noriaki ^a   Iguchi, Seitarou ^a   Karasawa, Ryo ^a   In, Hian ^a   Kawashima, Shinji ^a   Saito, Noriko ^a   Imai, Naofumi ^a   Saito, Kumiko ^a   Suzuki, Satoru ^b   Arakawa, Masaaki ^a   Gejyo, Fumitake ^a  

^a NIIGATA UNIVERSITY   (Japan)

^b UNIVERSITY OF FUKUI   (Japan)

Author keywords

Immunosuppressive agent; Interferon; Steroid

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA INTERFERON; ANTITHROMBOCYTIC AGENT; AZATHIOPRINE; CYCLOPHOSPHAMIDE; DIPYRIDAMOLE; IMMUNOSUPPRESSIVE AGENT; PREDNISOLONE; STEROID;

ADULT; AGED; ARTICLE; CENTRAL RETINA VEIN OCCLUSION; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG SAFETY; FEMALE; HEPATITIS C; HUMAN; KIDNEY BIOPSY; KIDNEY FUNCTION; LIVER DISEASE; LIVER FUNCTION; MALE; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS; PNEUMONIA; PROGNOSIS; REBOUND; REMISSION; SURVIVAL RATE; VIRUS INFECTION;

EID: 0033778314     PISSN: 09182918     EISSN: None     Source Type: Journal    
DOI: 10.2169/internalmedicine.39.788     Document Type: Article

References (30)

1. Bohle A, Wehrmann M, Bogenschutz O, et al. The long-term prognosis of primary glomerulonephritides. A morphological and clinical analysis of 1747 cases. Pathol Res Pract 188: 908-924, 1992.
2. Pedersen RS. Long-term prognosis in idiopathic membranoproliferative glomerulonephritis. Scand J Urol Nephrol 29: 265-272, 1995.
3. Kuo G, Choo QL, Alter HJ, et al. An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis. Science 244: 362-364, 1989.
4. Johnson RJ, Gretch DR, Yamabe H, et al. Membranoproliferative glomerulonephritis associated with hepatitis C virus infection. N Engl J Med 328: 465-470, 1993 (see comments).
5. Pucillo LP, Agnello V. Membranoproliferative glomerulonephritis associated with hepatitis B and C viral infections: from viruslike particles in the cryoprecipitate to viral localization in paramesangial deposits, problematic investigations prone to artifacts. Curr Opin Nephrol Hypertens 3: 465-470, 1994.
6. Yamabe H, Johnson RJ, Gretch DR, et al. Hepatitis C virus infection and membranoproliferative glomerulonephritis in Japan. J Am Soc Nephrol 6: 220-223, 1995.
7. Gumber SC, Chopra S. Hepatitis C: a multifaceted disease. Review of extrahepatic manifestations. Ann Intern Med 123: 615-620, 1995 (see coments).
8. Roithinger FX, Allinger S, Kirchgatterer A, et al. A lethal course of chronic hepatitis C, glomerulonephritis, and pulmonary vasculitis unresponsive to interferon treatment. Am J Gastroenterol 90: 1006-1008, 1995.
9. Rostoker G, Pawlotsky JM, Bastie A, Weil B, Dhumeaux D. Type I membranoproliferative glomerulonephritis and HCV infection. Nephrol Dial Transplant 11 Suppl 4: 22-24, 1996.
10. Ohta S, Yokoyama H, Wada T, et al. Exacerbation of glomerulonephritis in subjects with chronic hepatitis C virus infection after interferon therapy. Am J Kidney Dis 33: 1040-1048, 1999 (see comments).
11. Altraif IH, Abdulla AS, al Sebayel MI, Said RA, al Suhaibani MO, Jones AA. Hepatitis C associated glomerulonephritis. Am J Nephrol 15: 407-410, 1995.
12. Yamabe H, Johnson RJ, Gretch DR, et al. Membranoproliferative glomerulonephritis associated with hepatitis C virus infection responsive to interferon-alpha. Am J Kidney Dis 25: 67-69, 1995.
13. Agnello V. The etiology and pathophysiology of mixed cryoglobulinemia secondary to hepatitis C virus infection. Springer Semin Immunopathol 19: 111-129, 1997.
14. Lopes LM, Lopes EP, Silva E, et al. Prevalence of hepatitis C virus antibodies in primary glomerulonephritis in Brazil. Am J Nephrol 18: 495-497, 1998.
15. Botte C, Janot C. Epidemiology of HCV infection in the general population and in blood transfusion. Nephrol Dial Transplant 11 Suppl 4: 19-21, 1996.
16. Kuboki M, Shinzawa H, Shao L, et al. A cohort study of hepatitis C virus (HCV) infection in an HCV epidemic area of Japan: age and sex-related seroprevalence of anti-HCV antibody, frequency of viremia, biochemical abnormality and histological changes. Liver 19: 88-96, 1999.
17. Matsumori A. Molecular and immune mechanisms in the pathogenesis of cardiomyopathy - role of viruses, cytokines, and nitric oxide. Jpn Circ J 61: 275-291, 1997.
18. Matsumori A, Ohashi N, Hasegawa K, et al. Hepatitis C virus infection and heart diseases: a multicenter study in Japan. Jap Circ J 62: 389-391, 1998.
19. Levin A. Management of membranoproliferative glomerulonephritis: Evidence-based recommendations. Kidney Int Suppl 70: S41-S46, 1999.
20. Johnson RJ, Gretch DR, Couser WG, et al. Hepatitis C virus-associated glomerulonephritis. Effect of alpha-interferon therapy. Kidney Int 46: 1700-1704, 1994.
21. Sarac E, Bastacky S, Johnson JP. Response to high-dose interferon-alpha after failure of standard therapy in MPGN associated with hepatitis C virus infection. Am J Kidney Dis 30: 113-115, 1997.
22. Moses PL, Krawitt EL, Aziz W, Corwin HL. Renal failure associated with hepatitis C virus infection. Improvement in renal function after treatment with interferon-alpha. Dig Dis Sci 42: 443-446, 1997.
23. Daghestani L, Pomeroy C. Renal manifestations of hepatitis C infection. Am J Med 106: 347-354, 1999.
24. Brenard R. Practical management of patients treated with alpha interferon. Acta Gastroenterol Belg 60: 211-213, 1997.
25. Johnson ME, Fisher DG, Fenaughty A, Theno SA. Hepatitis C virus and depression in drug users. Am J Gastroenterol 93: 785-789, 1998.
26. Quigg RJ, Brathwaite M, Gardner DF, Gretch DR, Ruddy S. Successful cyclophosphamide treatment of cryoglobulinemic membranoproliferative glomerulonephritis associated with hepatitis C virus infection. Am J Kidney Dis 25: 798-800, 1995.
27. Komatsuda A, Imai H, Wakui H, et al. Clinicopathological analysis and therapy in hepatitis C virus-associated nephropathy. Internal Med 35: 529-533, 1996.
28. Roth D, Cirocco R, Zucker K, et al. De novo membranoproliferative glomerulonephritis in hepatitis C virus-infected renal allograft recipients. Transplantation 59: 1676-1682, 1995.
29. Cruzado JM, Gil-Vernet S, Ercilla G, et al. Hepatitis C virus-associated membranoproliferative glomerulonephritis in renal allografts. J Am Soc Nephrol 7: 2469-2475, 1996.
30. Pham HP, Feray C, Samuel D, et al. Effects of ribavirin on hepatitis C-associated nephrotic syndrome in four liver transplant recipients. Kidney Int 54: 1311-1319, 1998.